Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676156 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00676156 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 40 participants.
The verdict
NCT00676156, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about an investigational drug known as oral lipoic acid (LA) that may help treat multiple sclerosis. This study will measure how a person's body absorbs and breaks down the drug (pharmacokinetics) and will compare four different forms of the drug from four different manufacturers as well as LA in conjunction with fish oil.
Interventions
- DRUG oral lipoic acid (LA)
- DRUG lipoic acid (LA) with fish oil and LA without fish oil
- DRUG R lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676156
The ClinicalTrials.gov registry entry for NCT00676156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oral lipoic acid (LA) is the first listed.
NCT00676156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676156 about?
NCT00676156 is a clinical study titled "A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis". The purpose of this study is to learn about an investigational drug known as oral lipoic acid (LA) that may help treat multiple sclerosis. This study will measure how a person's body absorbs and breaks down the drug (pharmacokinetics) and will compare four different forms of the drug from four diffe...
What is the current status of trial NCT00676156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2005-12. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00676156?
The interventions under investigation include: oral lipoic acid (LA) (DRUG), lipoic acid (LA) with fish oil and LA without fish oil (DRUG), R lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00676156?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.